IMFINZI DOSING

Dosing and method of administration

INDIVIDUAL WEIGHT-BASED DOSING¹

• IMFINZI is supplied as single-use vials that contain either 500 mg/10 mL or 120 mg/2.4 mL.¹ Refer to the IMFINZI SmPC for further information on storage, dilution, and administration instructions
• Treatment must be initiated and supervised by a physician experienced in the treatment of cancer¹
• Infusion-related reactions with IMFINZI were observed in 1.9% of patients in the PACIFIC study¹

It is recommended to continue treatment for clinically stable patients with initial evidence of disease progression until disease progression is confirmed.¹

Continue treatment with IMFINZI for 12 months in the absence of disease progression or unacceptable toxicity¹